Factor H Antibody (Monoclonal - #2)

A murine monoclonal antibody to human Factor H


Product Specifications

Citations5
Clonality

Monoclonal

Immnogen

Purified human protein.

Applications

See citations and technical data sheet for application info.

Concentration1.0-1.2 mg/mL
ConjugateUnconjugated
Cross Reactivity

Human, Baboon, Cynomolgus Monkey

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog NumberA254
Catalog Number (CE)N/A
Size100 µl
Price (USD)$365.00
Price (EURO)330,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

A murine monoclonal antibody to human Factor H

Size

100 µl

Concentration1.0-1.2 mg/mL
ApplicationsSee citations and technical data sheet for application info.
FormLiquid. Borate Buffered Saline (pH 8.4 ± 0.2), with ≤ 0.1% Sodium Azide.
ClonalityMonoclonal
Immunogen

Purified human protein.

ConjugateUnconjugated
Cross ReactivityHuman, Baboon, Cynomolgus Monkey
Isotype

IgG1k

Purity

> 95% by SDS PAGE

SourceMouse
Specificity

This monoclonal antibody was raised against purified human Factor H.

Storage

Short term (30 days) 4˚C. Long term at or below –20˚C.

Background

Factor H is a fluid phase complement regulatory protein consisting of a single peptide chain of 20 short consensus repeat segments or CCP’s with a molecular weight of approximately 155 KD. Factor H regulates the alternative pathway of the complement system by modifying activity of the “feedback loop.” It does this in three ways. First, it is a co-factor for the serine protease Factor I, which cleaves C3b to iC3b. iC3b has no hemolytic or amplification function, but may be bound by complement receptors. Second, Factor H prevents the formation of and accelerates the disassociation of the alternative pathway C3 convertase, C3bBb from cell surfaces. Finally, Factor H binds to polyanions on host cell surfaces and tissue matrices, such as basement membranes, blocking deposition of C3b. This later activity is leveraged by many pathogens as a mode of complement evasion. Recent studies have linked Factor H to hemolytic uremia syndrome (HUS), age-related macular degeneration (AMD), 4 and membrano-proliferative glomerulonephritis. Factor H may also be elevated in certain cancers, including bladder cancer, potentially as a protective measure used by tumor cells to evade complement attack.